Introduction
============

Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related death worldwide, with an estimated 1.0 million new cases of gastric cancer and 723100 deaths due to gastric cancer in 2012 [@B1]. The burden caused by gastric cancer is growing worldwide, particularly in developing countries [@B2].

The incidence of gastric cancer has decreased over the last 50 years. Meanwhile, differential trends have also occurred, such as an increase in the diffuse type, particularly signet ring cell (SRC). Henson et al. reported that SRC has increased on average 6.5% per year from 1973 to 2000 in the United States [@B3]. SRC is a histological subtype of carcinoma with cells containing large amounts of intracytoplasmic mucins [@B4].

SRC was classified as one of the undifferentiated gastric carcinomas according to the Japanese Gastric Cancer Association [@B5]. It was reported that patients with SRC tend to be young females, and SRC patients tend to have more lymph node involvement and even peritoneal seeding [@B6], which indicates a more aggressive stage of SRC. However, the prognostic value of gastric cancer with SRC remains controversial. Several studies have reported that SRC is a poor prognostic factor for gastric cancer [@B6]-[@B11], while others have argued that gastric cancer patients with SRC have better survival [@B12]-[@B15]. Therefore, we aimed to perform a meta-analysis to evaluate the prognostic value of SRC in gastric cancer.

Methods
=======

Search strategy and study selection
-----------------------------------

On July 1st, 2017, relevant articles were systematically and independently searched by two authors (RC, Nie and SQ, Yuan) in PubMed and Web of Science using the key words "gastric cancer", "gastric carcinoma", "gastric neoplasm", and "signet ring cell", limited to Abstract/Title. We also checked the reference lists of the articles retrieved manually to identify additional relevant articles.

According to the WHO criteria, SRC was defined by an adenocarcinoma with more than 50% of the tumor consisting of isolated or small groups of malignant cells containing intracytoplasmic mucins [@B4]. Studies were included if they compared SRC and non-SRC directly with more than 50 patients involved in the studies. Studies were excluded if they were basic studies about animals or cells, review articles, meta-analyses, abstracts, case reports, case series, letters, conference proceedings or non-English published articles. Studies were also excluded if they did not conform to or mention the WHO criteria. If multiple reports described the same population, the most recent or complete research was included.

Data extraction
---------------

The data from the included studies were extracted independently by two authors (RC, Nie and YQ, Yuan). The adjudicating senior authors (S, Chen and YB, Chen) were responsible for resolving any disagreements. The following information was extracted from each study: first author, year of publication, country, stage of disease, sample size and SRC/non-SRC ratio. We also extracted the following clinicopathological characteristics: age, gender, tumor location, tumor size, lymph node involvement, lymphovascular invasion, perineural invasion, early disease ratio, gross type, peritoneal dissemination, hematogenous metastasis, and overall survival (OS).

Statistical analysis
--------------------

The estimated odds ratio (OR) or weighted mean difference (WMD) was used to summarize the association between SRC pathological type and different clinicopathological characteristics. The hazard ratio (HR) was pooled to analyze the OS results as demonstrated by Parmar et al. [@B16]. All results were reported with 95% confidence intervals (CIs). Heterogeneity was assessed using the χ² test and quantified using the I^2^ statistic, with the level of significance set at 10%.

The fixed-effects model was used when P \>0.1; otherwise, the random-effects model was used [@B17]. The publication bias was tested by Begg\'s linear regression [@B18]. A P value of \< 0.05 was considered significant. Analyses were performed using STATA SE 12.0 (StataCorp, College Station, TX, USA).

Results
=======

Study selection
---------------

Based on the inclusion and exclusion criteria, a total of 20 studies [@B6]-[@B15], [@B19]-[@B28] including 35947 cases were included in the final analysis (Fig. [1](#F1){ref-type="fig"}). The characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}. These studies were primarily from six countries (Japan, Korea, China, France, America, and Belgium) and were published from 1992 to 2017. The proportion of SRC ranged from 3.4% to 50.0% in the included studies.

Clinicopathological characteristics
-----------------------------------

The relationships between the clinicopathological characteristics and SRC were investigated. Compared with non-SRC patients, SRC patients tended to be younger (WMD: -3.88, 95% CI: -6.19- -1.56, P=0.001; I^2^=92.5%, P\<0.001; Fig. [2](#F2){ref-type="fig"}A) and predominantly female (OR: 1.60, 95% CI: 1.34-1.91, P\<0.001; I^2^=84.4%, P\<0.001; Fig. [2](#F2){ref-type="fig"}B). Additionally, SRC patients exhibited less upper third tumor location (OR: 0.62, 95% CI: 0.47-0.81, P\<0.001; I^2^=82.0%, P\<0.001; Fig. [2](#F2){ref-type="fig"}C). There were no differences between SRC and non-SRC patients with regard to tumor size (WMD: -0.26 cm, 95% CI: -0.86- 0.33, P=0.390; I^2^=92.2%, P\<0.001; Fig. [2](#F2){ref-type="fig"}D), early gastric cancer ratio (OR: 1.58, 95% CI: 0.87-2.86, P=0.130; I^2^=96.6%, P\<0.001; Fig. [2](#F2){ref-type="fig"}E), lymph node involvement (OR: 0.83, 95% CI: 0.61-1.14, P=0.247; I^2^=93.2%, P\<0.001; Fig. [2](#F2){ref-type="fig"}F), lymphovascular invasion (OR: 0.96, 95% CI: 0.66-1.40, P=0.822; I^2^=84.9%, P\<0.001; Fig. [2](#F2){ref-type="fig"}G), or peritoneal dissemination (OR: 1.17, 95% CI: 0.97-1.42, P=0.092; I^2^=47.3%, P=0.077; Fig. [2](#F2){ref-type="fig"}H). However, patients with SRC exhibited less frequent hematogenous metastasis (OR: 0.41, 95% CI: 0.27-0.64, P\<0.001; I^2^=17.9%, P=0.294; Fig. [2](#F2){ref-type="fig"}I).

With regard to early gastric cancer, there was no difference in tumor size (WMD: 0.15 cm, 95% CI: -0.25- 0.55, P=0.460; I^2^=77.2%, P=0.002; Fig. [3](#F3){ref-type="fig"}A). However, patients with SRC had a higher frequency of the depressed gross type (OR: 2.11, 95% CI: 1.11-3.98, P=0.022; I^2^=76.7%, P=0.002; Fig. [3](#F3){ref-type="fig"}B), more mucosal invasion (OR: 1.68, 95% CI: 1.24-2.29, P=0.001; I^2^=75.3%, P\<0.001; Fig. [3](#F3){ref-type="fig"}C), and marginally less lymph node metastasis (OR: 0.68, 95% CI: 0.46-1.01, P=0.054; I^2^=69.5%, P=0.001; Fig. [3](#F3){ref-type="fig"}C).

The comparison of the major characteristics of advanced gastric cancer between SRC and non-SRC are shown in Figure [4](#F4){ref-type="fig"}. Compared with non-SRC, SRC was associated with marginally larger tumor size (WMD: 0.63 cm, 95% CI: -0.01- 1.13, P=0.059; I^2^=54.7%, P=0.039; Fig. [4](#F4){ref-type="fig"}A) and increased Borrmann IV type (OR: 3.29, 95% CI: 2.02-5.34, P\<0.001; I^2^=88.1%, P\<0.001; Fig. [4](#F4){ref-type="fig"}B). Although there were no differences in T4 invasion (OR: 0.88, 95% CI: 0.61-1.27, P=0.497; I^2^=85.6%, P\<0.001; Fig. [4](#F4){ref-type="fig"}C) and lymph node metastasis (OR: 0.80, 95% CI: 0.58-1.11, P=0.183; I^2^=81.4%, P\<0.001; Fig. [4](#F4){ref-type="fig"}D) between SRC and non-SRC, patients with SRC tended to have more peritoneal dissemination (OR: 1.69, 95% CI: 1.41-2.02, P\<0.001; I^2^=43.5%, P=0.115; Fig. [4](#F4){ref-type="fig"}E).

Overall survival
----------------

In this meta-analysis, a total of 15 studies [@B6]-[@B15], [@B22], [@B24]-[@B28] were available for the pooled HR of OS. There was significant heterogeneity among the studies for the pooled HR of OS (I^2^=89.8%, P\<0.001; Fig. [5](#F5){ref-type="fig"}A); therefore, the random-effects model was used. The pooled HR was 1.02 (95% CI: 0.87-1.19, P=0.830), indicating no difference in OS between the SRC and non-SRC patients. In the subgroup analysis, early gastric cancer with SRC was associated with a better prognosis with a pooled HR of 0.57 (95% CI: 0.40-0.81, P=0.002), with significant heterogeneity (I^2^=70.6%, P\<0.001; Fig. [5](#F5){ref-type="fig"}B). However, the pooled HR for advanced gastric cancer with SRC was 1.17 (95% CI: 1.10-1.25, P\<0.001), with no significant heterogeneity (I^2^=29.5%, P=0.214; Fig. [5](#F5){ref-type="fig"}C).

Publication bias
----------------

In the present meta-analysis, Begg\'s linear regression was performed to assess the publication bias of OS. There was no publication bias detected for OS (P=0.374) (Fig. [6](#F6){ref-type="fig"}).

Discussion
==========

Although the incidence of gastric cancer is decreasing, the proportion of SRC in gastric cancer has tended to increase [@B3]. The definition of gastric SRC is not based on biological behavior but on microscopic features of the cancer. SRC was classified as a diffuse type by the Lauren classification [@B29], as an infiltrative type by the Ming classification [@B30], and as an undifferentiated type by the WHO classification criteria [@B4]. Previous studies of the characteristics and prognostic value of SRC in gastric cancer have yielded inconsistent results [@B6]-[@B15], [@B19]-[@B28], [@B31], [@B32] and, therefore, remain controversial. Therefore, we performed the present meta-analysis to investigate the characteristics and prognostic value of SRC in gastric cancer. The pooled results of OS demonstrated that there was no difference in OS between SRC and non-SRC patients in the total population. However, SRC was associated with a better prognosis in early gastric cancer but worse survival in advanced gastric cancer.

Our results showed that SRC tended to affect younger female patients, and SRC tended to be located in the middle and lower third of the stomach. The association between sex and SRC may be due to sex hormones. It has been reported that levels of the estrogen receptor were higher in young women and in patients with poorly differentiated gastric cancer [@B33].

Early gastric cancer is defined as a lesion confined to the mucosa or submucosa, regardless of the status of lymph node metastasis [@B34]. The prognostic value of SRC in early gastric cancer is debatable. Wang et al. reported that early gastric cancer with SRC was associated with a lower incidence of lymph node involvement and a longer 5-year survival (93.9% vs. 85.8%, P=0.027) [@B15], in accordance with several studies [@B13], [@B14], [@B22], [@B24], [@B25], [@B27]. However, other studies showed that there was no difference in survival between SRC and non-SRC patients [@B7], [@B10], [@B26]. The present meta-analysis revealed that SRC is a better prognostic factor for early gastric cancer (HR: 0.57, P=0.002), which is characterized by a higher proportion of the depressed gross type (OR: 2.11, P=0.022), more mucosal invasion (OR: 1.68, P=0.001), and marginally less lymph node metastasis (OR: 0.68, P=0.054). A higher percentage of the depressed type and the distinct feature of enriched intracytoplasmic mucins with the nucleus compressed peripherally may lead to early detection of the tumor by gastroscopy and biopsy [@B20]. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been associated with excellent prognoses [@B35], [@B36]. EMR and ESD are recommended for early-stage gastric cancer lesions smaller than 2 cm in diameter without relevant ulcer formation [@B37]. Therefore, considering the lower incidence of lymph node metastasis and better prognosis, less invasive gastric surgery, such as EMR, ESD, or gastrectomy with D1 lymphadenectomy, is highly recommended for patients with early SRC.

A report by Li et al. showed that advanced gastric SRC had deeper tumor invasion, more lymph node metastasis, and peritoneal dissemination, resulting in a worse prognosis [@B6]. However, a study by Jiang et al. reported that no significant difference in survival was observed between SRC and non-SRC patients with advanced gastric cancer [@B25]. Our result showed that SRC was associated with larger tumor size (WMD: 0.63 cm, P=0.059), an increase in Borrmann IV type (OR: 3.29, P\<0.001), and more peritoneal dissemination (OR: 1.69, P\<0.001). The pooled HR of 1.17 (P\<0.001) also indicated a worse prognosis for SRC patients with advanced gastric cancer. Therefore, more radical surgery should be performed for patients with advanced gastric cancer with SRC.

The underlying cause for the opposite prognoses for patients with early and advanced gastric cancer with SRC remains uncertain. One explanation is that early SRC is associated with a low aggressive state because of a CDH1 mutation [@B38]. When SRC has invaded the muscularis propria, it will accelerate tumor invasion, increase the risk of lymph node metastasis and peritoneal seeding, and worsen the chemosensitivity and prognosis [@B27].

There are some limitations in the present meta-analysis that must be considered. First, the main limitation is that all the included studies were retrospective studies from different countries, with the proportion of SRC ranging from 3.4% to 50.0%. Second, there is significant between-study heterogeneity in our meta-analysis. However, we included the studies strictly according to the WHO criteria for SRC, and we used a random-effects model to address heterogeneity appropriately.

Conclusions
===========

This meta-analysis indicated that SRC tends to affect young females and tends to be located in the middle and lower third of the stomach. Early SRC patients have better prognoses than non-SRC patients, while advanced SRC patients exhibited the worse prognoses.
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###### 

Characteristics of the included studies

  Author              Year   Country       Stage            No. of patients   SRC/non-SRC (%)   HR for OS (SRC vs. non-SRC)
  ------------------- ------ ------------- ---------------- ----------------- ----------------- -----------------------------
  Maehara et al.      1992   Japan         all stage        1500              3.4% vs. 96.6%    NA
  Otsuji et al.       1998   Japan         all stage        1498              10.3% vs. 89.7%   NA
  Hyung et al.        2002   Korea         early stage      933               28.2% vs. 71.8%   0.58
  Kim et al.          2004   Korea         all stage        2358              8.7% vs. 91.3%    NA
  Kunisaki et al.     2004   Japan         all stage        1113              15.6% vs. 84.4%   0.20**^a^**
  Li et al.           2007   Korea&China   advanced stage   4759              13.9% vs. 86.1%   1.16
  Piessen et al.      2009   France        all stage        215               32.5% vs. 67.5%   1.81**^b^**
  Lee et al.          2010   Korea         early stage      1326              33.8% vs. 66.2%   NA
  Zhang et al.        2010   China         all stage        1439              15.1% vs. 84.9%   1.28
  Chiu et al.         2011   China         all stage        2439              20.7% vs. 79.3%   1.01
  Jiang et al.        2011   China         all stage        2315              9.1% vs. 90.9%    0.72
  Gronnier et al.     2013   France        early stage      421               25% vs. 75%       0.56
  Nafteux et al.      2014   Belgium       all stage        920               12.4% vs. 87.6%   1.60
  Liu et al.          2015   China         all stage        1464              9.4% vs. 90.6%    1.45
  Postlewait et al.   2015   America       all stage        768               40.6% vs. 59.4%   1.19
  Wang et al.         2015   China         early stage      334               34.4% vs. 65.6%   0.40
  Kong et al.         2016   China         N-stage**^c^**   480               18.8% vs. 81.2%   1.29
  Lu et al.           2016   China         all stage        2199              16.1% vs. 83.9%   1.25
  Voron et al.        2016   France        all stage        1799              50.0% vs. 50.0%   1.47
  Chon et al.         2017   Korea         all stage        7667              21.5% vs. 78.5%   0.75

SRC, signet ring cell carcinoma; HR, hazard ratio; OS, overall survival; NA, not available;

a, HR was only available for early stage;

b, HR for resected patients;

c, Study including only node-negative gastric cancer.
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